NDATOPICALSOLUTION
Approved
Mar 2000
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
3
Data completeness
3/8 — Basic
Drug data last refreshed 18h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LAMISIL AT is a topical antifungal solution containing terbinafine hydrochloride, approved in 2000 for the treatment of fungal skin infections including athlete's foot, jock itch, and ringworm. It works by inhibiting fungal cell wall synthesis, making it effective against dermatophytes and other fungal pathogens. The product is available as an over-the-counter topical solution.
LOE Approaching
As LOE approaches, the brand team is likely consolidating and focusing on retention strategies; opportunities may shift toward generic support or transition planning rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (3)
SINGLE-APPLICATION TERBINAFINE HYDROCHLORIDE (1%) TOPICAL LIQUID SOLUTION VERSUS A SINGLE-APPLICATION BUTENAFINE HYDROCHLORIDE (1%) TOPICAL LIQUID SOLUTION FOR THE TREATMENT OF TINEA PEDIS
Started Jan 2019
42 enrolled
Tinea Pedis
Bioequivalence Study of Terbinafine Hydrochloride Tablets, 250 mg of Dr. Reddy's Under Fed Conditions
Started Jan 2002
18 enrolled
Healthy
Bioequivalence Study of Terbinafine Hydrochloride Tablets, 250 mg of Dr. Reddy's Under Fasting Conditions
Started Jan 2002
36 enrolled
Fasting
Career Relevance
Working on LAMISIL AT offers limited career growth opportunities given its LOE status and minimal linked job postings; the role is best suited for professionals seeking stability in mature product management or those transitioning to generic/OTC portfolio roles. Career advancement typically requires lateral moves to growth-stage products or organizational transitions to support LOE strategy.
Worked on LAMISIL AT at Bayer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.